[11C]‐DASB, a tool for in vivo measurement of SSRI‐induced occupancy of the serotonin transporter: PET characterization and evaluation in cats
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The in vivo pharmacological profile of [11 C]‐DASB, a new radioligand developed for in vivo imaging of the serotonin transporter (SERT), was evaluated in the cat brain using positron emission tomography (PET). The in vivo distribution of [11 C]‐DASB binding was consistent with the known distribution of SERT sites in the cat brain in vitro with high uptakes of radioactivity in the midbrain and thalamus, intermediate levels in striatum, and modest to low levels of radioactivity in the neocortex and cerebellum, respectively. [11 C]‐DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain. Radioligand binding in all brain regions except cerebellum was markedly reduced following pretreatment with fluoxetine and citalopram, but was unaffected by pretreatment with GBR12909, maprotiline, and haloperidol, indicating specificity of [11 C]‐DASB binding to the SERT. Two cats were each examined using PET and [11 C]‐DASB in a longitudinal fashion (from 30 min and up to 24 days) following a single i.v. dose of: 1) fluoxetine, and 2) citalopram at different dosages. Both drugs induced similar degrees of SERT occupancy at 30 min postinjection (∼90%). A comparison of citalopram and fluoxetine pharmacokinetics in the same animal and at the same dosage (1 mg/kg) showed that citalopram SERT occupancy and plasma half‐lives were 9 times and 14 times shorter, respectively, than those of fluoxetine and norfluoxetine. In addition, studies performed after injection of the monoamine oxidase inhibitor tranylcypromine suggested that high levels of synaptic serotonin may compete with [11 C]‐DASB for binding on the SERT. These studies indicate that [11 C]‐DASB is a suitable PET radioligand for measuring drug occupancy of the SERT in vivo and has potential for monitoring in vivo changes in serotonin levels. Synapse 47:123–133, 2003. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Malison, R. T., Price, L. H., Berman, R., van Dyck, C. H., Pelton, G. H., Carpenter, L., Sanacora, G., Owens, M. J., Nemeroff, C. B., Rajeevan, N., et al. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00272-8 · Cited by 496
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492 · cited 1×
“These results are consistent with in vivo and in vitro studies showing that citalopram is more potent than fluoxetine at inhibiting serotonin reuptake (Hyttel, 1994; Sitte et al., 2000).”
Imaging endogenous dopamine competition with [11C]raclopride in the human brain
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., et al. (1994) · Synapse · doi:10.1002/syn.890160402 · Cited by 379 · cited 1×
“Indeed, the binding [11C]raclopride in the striatum of nonhuman primates is decreased by drugs that elevate synaptic dopamine and is increased by drugs that decrease synaptic dopa- mine (Hume et al., 1992; Dewey et al., 1993; Volkow et al., 1994; Ginovart et al., 1997).”
BackgroundPreskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370
Houle, S., Ginovart, N., Hussey, D., Meyer, J. H., & Wilson, A. A. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000365 · Cited by 276 · cited 1×
“…of SERT in the brain and that, due to the favorable binding kinetics of [11C]-DASB, reliable estimates of SERT sites densities can be obtained using simplified methods of quantification which do not require arterial sampling or plasma metabolite analysis (Houle et al., 2000; Ginovart et al., 2001).”
Self-citationHenry, M. E., Moore, C. M., Kaufman, M. J., Michelson, D., Schmidt, M. E., Stoddard, E., Vuckevic, A. J., Berreira, P. J., Cohen, B. M., & Renshaw, P. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1506 · Cited by 61
Cited by
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Self-citationSeasonal Variation in Human Brain Serotonin Transporter Binding
Praschak-Rieder, N., Willeit, M., Wilson, A. A., Houle, S., & Meyer, J. H. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.9.1072 · Cited by 278
Self-citationMeyer, J. H. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0709 · Cited by 272
Self-citationFinberg, J. P. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.010 · Cited by 257
Cannon, D. M., Ichise, M., Fromm, S. J., Nugent, A. C., Rollis, D., Gandhi, S. K., Klaver, J. M., Charney, D. S., Manji, H. K., & Drevets, W. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.005 · Cited by 197
Metadata
- Authors
- Ginovart, N., Wilson, A. A., Meyer, J. H., Hussey, D., & Houle, S.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2002-11-26
- Volume
- 47
- Issue
- 2
- Pages
- 123-133
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2032994066
- Cited by
- 72
- References
- 7
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.